Valiant Laboratories

VALIANTLAB

Q: How strong is Valiant Laboratories balance sheet?

Balance sheet of Valiant Laboratories is strong.It shouldn't have solvency or liquidity issues.

Q: Is the debt of Valiant Laboratories increasing or decreasing?

Yes, The net debt of Valiant Laboratories is increasing.Latest net debt of Valiant Laboratories is ₹45.21 Crs as of Mar-25.This is greater than Mar-24 when it was -₹124.71 Crs.

Q: Is Valiant Laboratories stock expensive?

Valiant Laboratories is not expensive.Latest PE of Valiant Laboratories is 0.0, while 3 year average PE is 9.53. Also latest EV/EBITDA of Valiant Laboratories is 0.0 while 3yr average is 11.6.

Price

Micro Cap

₹468 Cr.

New to Zerodha? Sign-up for free.

Valiant Laboratories is in the Healthcare sector with a M.cap of 468.00 Cr and a PE ratio of 0.0.

Low

75.20

52W Range

High

157

Sector PE

27.82

P/B

2.0

Div.Yield

ROE

0.13%

EBIDTA

ROCE

-0.22

EPS

0.16

New to Zerodha? Sign-up for free.

Share Price
Financials
Revenue mix
Shareholdings
Peers
Forensics

This data is currently unavailable for this company.

Summary
Profit & Loss
Balance sheet
Cashflow

View Detailed Summary

This data is currently unavailable for this company.

Yearly | Quarterly

(In Cr.)

(In Cr.)
This data is currently unavailable for this company.

Financial Ratio's

(In %)

Detailed P&L Report

(In Cr.)

Detailed Balance Sheet

Financial Year (In Cr.)

Detailed Cash Flow

Product wise
Location wise

VALIANTLAB
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

VALIANTLAB
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

More Info

Shareholdings

Holders

Detailed Shareholdings

This data is currently unavailable for this company.

Peers

Detailed Peers

Forensics

View Detailed Forensics

Recent events

News
Corporate Actions

India's Valiant Laboratories Sept-Quarter Consol Net Profit Falls

Nov 06, 2023

Indian paracetamol maker Valiant Laboratories lists at 16% premium

Oct 06, 2023

Indian paracetamol maker Valiant Laboratories lists at 16% premium

BENGALURU, Oct 6 (Reuters) - Shares of Indian pharmaceutical company Valiant Laboratories VALO.NS rose 15.8% in their trading debut on Friday, valuing the company at 5.28 billion rupees ($63.5 million).

The initial public offering of the Mumbai-based maker of paracetamol tablets was oversubscribed 29.8 times, with retail investors bidding 16 times and high net-worth investors 73.6 times.

The offering had fresh issue of shares worth 1.62 billion rupees ($19.5 million) at the top end of the 133-140 rupees price range.

Valiant is involved in the business of manufacturing active pharmaceutical ingredients (API) for pain killer drug Paracetamol.

Valiant competes with larger rivals such as Granules GRAN.NS and Glenmark Life Sciences GLEM.NS in the API market.

Earlier this week, Indian commercial port operator JSW Infrastructure's JSWN.NS listing saw a bumper opening with shares surging more than 32%.

($1 = 83.2025 Indian rupees)

(Reporting by Sethuraman NR and Kashish Tandon in Bengaluru; Editing by Sohini Goswami)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

Indian paracetamol maker Valiant Laboratories lists at 16% premium

The initial public offering of the Mumbai-based maker of paracetamol tablets was oversubscribed 29.8 times, with retail investors bidding 16 times and high net-worth investors 73.6 times.

The offering had fresh issue of shares worth 1.62 billion rupees ($19.5 million) at the top end of the 133-140 rupees price range.

Valiant is involved in the business of manufacturing active pharmaceutical ingredients (API) for pain killer drug Paracetamol.

Valiant competes with larger rivals such as Granules GRAN.NS and Glenmark Life Sciences GLEM.NS in the API market.

Earlier this week, Indian commercial port operator JSW Infrastructure's JSWN.NS listing saw a bumper opening with shares surging more than 32%.

($1 = 83.2025 Indian rupees)

(Reporting by Sethuraman NR and Kashish Tandon in Bengaluru; Editing by Sohini Goswami)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

Annual Report

Announcement Date

Jul 17, 2024

Quarterly Results

Announcement Date

Feb 09, 2024

Quarterly Results

Announcement Date

Nov 06, 2023

More Micro Cap Ideas

See similar 'Micro' cap companies with recent activity

Promoter Buying

Companies where the promoters are bullish

Detailed List

Capex

Companies investing on expansion

Detailed List

Superstar Investor

Companies where well known investors have invested

Detailed List

VALIANTLAB

Share Price

Financials

Revenue mix

Shareholdings

Peers

Forensics

Summary

Profit & Loss

Balance sheet

Cashflow

Product wise

Location wise

Recent events

News

Corporate Actions

India's Valiant Laboratories Sept-Quarter Consol Net Profit Falls

Indian paracetamol maker Valiant Laboratories lists at 16% premium

Events:

Quarterly Results

Quarterly Results

Quarterly Results

Quarterly Results

Quarterly Results

Quarterly Results

More Micro Cap Ideas

Promoter Buying

Capex

Superstar Investor

Popular questions

Business

Financials

Share Price

Shareholdings

What does Valiant Laboratories do?

Who are the competitors of Valiant Laboratories?

Is Valiant Laboratories financially stable compared to its competitors?

Does Valiant Laboratories pay decent dividends?

How has Valiant Laboratories allocated its funds?

How strong is Valiant Laboratories balance sheet?

Is the profitablity of Valiant Laboratories improving?

Is the debt of Valiant Laboratories increasing or decreasing?

Is Valiant Laboratories stock expensive?

Has the share price of Valiant Laboratories grown faster than its competition?

Is the promoter bullish about Valiant Laboratories?

Are mutual funds buying/selling Valiant Laboratories?